316 related articles for article (PubMed ID: 21839578)
1. Combination of BAY 60-4552 and vardenafil exerts proerectile facilitator effects in rats with cavernous nerve injury: a proof of concept study for the treatment of phosphodiesterase type 5 inhibitor failure.
Oudot A; Behr-Roussel D; Poirier S; Sandner P; Bernabé J; Alexandre L; Giuliano F
Eur Urol; 2011 Nov; 60(5):1020-6. PubMed ID: 21839578
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effects of BAY 60-4552 and vardenafil on relaxation of corpus cavernosum tissue of patients with erectile dysfunction and clinical phosphodiesterase type 5 inhibitor failure.
Albersen M; Linsen L; Tinel H; Sandner P; Van Renterghem K
J Sex Med; 2013 May; 10(5):1268-77. PubMed ID: 23421435
[TBL] [Abstract][Full Text] [Related]
3. Are we finally on the right track in treating "difficult" erectile dysfunction patients?
Mirone V; Verze P
Eur Urol; 2011 Nov; 60(5):1027-8. PubMed ID: 21893378
[No Abstract] [Full Text] [Related]
4. Vardenafil and resveratrol synergistically enhance the nitric oxide/cyclic guanosine monophosphate pathway in corpus cavernosal smooth muscle cells and its therapeutic potential for erectile dysfunction in the streptozotocin-induced diabetic rat: preliminary findings.
Fukuhara S; Tsujimura A; Okuda H; Yamamoto K; Takao T; Miyagawa Y; Nonomura N; Okuyama A
J Sex Med; 2011 Apr; 8(4):1061-71. PubMed ID: 21269399
[TBL] [Abstract][Full Text] [Related]
5. Reduction of obstruction related bladder overactivity by the guanylyl cyclase modulators BAY 41-2272 and BAY 60-2770 alone or in combination with a phosphodiesterase type 5 inhibitor.
Füllhase C; Hennenberg M; Sandner P; Strittmatter F; Niedworok C; Bauer RM; Gratzke C; Soler R; Stief C; Andersson KE
Neurourol Urodyn; 2015 Nov; 34(8):787-93. PubMed ID: 25230878
[TBL] [Abstract][Full Text] [Related]
6. Chronic vardenafil treatment improves erectile function via structural maintenance of penile corpora cavernosa in rats with acute arteriogenic erectile dysfunction.
Hotta Y; Hattori M; Kataoka T; Ohno R; Mikumo M; Maeda Y; Kimura K
J Sex Med; 2011 Mar; 8(3):705-11. PubMed ID: 21143425
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo effects of vardenafil (a PDE-5 Inhibitor) on corpus cavernosal smooth muscle relaxation in diabetic rabbits.
Lau DH; Mumtaz FH; Mikhailidis DP; Thompson CS
Urol Int; 2009; 82(1):101-7. PubMed ID: 19172107
[TBL] [Abstract][Full Text] [Related]
8. Vardenafil improves penile erection in type 2 diabetes mellitus patients with erectile dysfunction: role of tropomyosin.
Zamorano-León JJ; Olivier C; de Las Heras N; Mateos-Cáceres PJ; Brime Menéndez R; Rodríguez-Sierra P; Martín Palacios N; Manso LS; Modrego J; Segura A; Macaya C; López-Farré AJ
J Sex Med; 2013 Dec; 10(12):3110-20. PubMed ID: 24112450
[TBL] [Abstract][Full Text] [Related]
9. Sustained soluble guanylate cyclase stimulation offsets nitric-oxide synthase inhibition to restore acute cardiac modulation by sildenafil.
Nagayama T; Zhang M; Hsu S; Takimoto E; Kass DA
J Pharmacol Exp Ther; 2008 Aug; 326(2):380-7. PubMed ID: 18456872
[TBL] [Abstract][Full Text] [Related]
10. Prolonged therapy with the soluble guanylyl cyclase activator BAY 60-2770 restores the erectile function in obese mice.
Silva FH; Leiria LO; Alexandre EC; Davel AP; Mónica FZ; De Nucci G; Antunes E
J Sex Med; 2014 Nov; 11(11):2661-70. PubMed ID: 25196910
[TBL] [Abstract][Full Text] [Related]
11. The functional and structural consequences of cavernous nerve injury are ameliorated by sildenafil citrate.
Mulhall JP; Müller A; Donohue JF; Mullerad M; Kobylarz K; Paduch DA; Tal R; Li PS; Cohen-Gould L; Scardino PT
J Sex Med; 2008 May; 5(5):1126-1136. PubMed ID: 18331274
[TBL] [Abstract][Full Text] [Related]
12. Endothelial rehabilitation: the impact of chronic PDE5 inhibitors on erectile function and protein alterations in cavernous tissue of diabetic rats.
De Young LX; Domes T; Lim K; Carson J; Brock GB
Eur Urol; 2008 Jul; 54(1):213-20. PubMed ID: 18342431
[TBL] [Abstract][Full Text] [Related]
13. Chronic administration of udenafil, a selective phosphodiesterase type 5 inhibitor, promotes erectile function recovery in an animal model of bilateral cavernous nerve crush injury.
Lee CH; Kim HS; Goo MJ; Kang KK; Ahn BO; Kim SH; Yang DY
J Sex Med; 2011 May; 8(5):1330-40. PubMed ID: 21366883
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of phosphodiesterase 5 (PDE 5) inhibit the nerve-induced release of nitric oxide from the rabbit corpus cavernosum.
Hallén K; Wiklund NP; Gustafsson LE
Br J Pharmacol; 2007 Feb; 150(3):353-60. PubMed ID: 17179943
[TBL] [Abstract][Full Text] [Related]
15. The effects of cyclic guanylate cyclase stimulation on right ventricular hypertrophy and failure alone and in combination with phosphodiesterase-5 inhibition.
Andersen A; Nielsen JM; Holmboe S; Vildbrad MD; Nielsen-Kudsk JE
J Cardiovasc Pharmacol; 2013 Aug; 62(2):167-73. PubMed ID: 23575263
[TBL] [Abstract][Full Text] [Related]
16. Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract.
Fibbi B; Morelli A; Vignozzi L; Filippi S; Chavalmane A; De Vita G; Marini M; Gacci M; Vannelli GB; Sandner P; Maggi M
J Sex Med; 2010 Jan; 7(1 Pt 1):59-69. PubMed ID: 19796053
[TBL] [Abstract][Full Text] [Related]
17. FK506 and sildenafil promote erectile function recovery after cavernous nerve injury through antioxidative mechanisms.
Lagoda G; Jin L; Lehrfeld TJ; Liu T; Burnett AL
J Sex Med; 2007 Jul; 4(4 Pt 1):908-16. PubMed ID: 17627738
[TBL] [Abstract][Full Text] [Related]
18. Effect of the phosphodiesterase 5 inhibitors sildenafil, tadalafil and vardenafil on rat anococcygeus muscle: functional and biochemical aspects.
Toque HA; Priviero FB; Zemse SM; Antunes E; Teixeira CE; Webb RC
Clin Exp Pharmacol Physiol; 2009 Apr; 36(4):358-66. PubMed ID: 18986324
[TBL] [Abstract][Full Text] [Related]
19. Vardenafil improved patient satisfaction with erectile hardness, orgasmic function and sexual experience in men with erectile dysfunction following nerve sparing radical prostatectomy.
Nehra A; Grantmyre J; Nadel A; Thibonnier M; Brock G
J Urol; 2005 Jun; 173(6):2067-71. PubMed ID: 15879836
[TBL] [Abstract][Full Text] [Related]
20. The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats.
Lang M; Kojonazarov B; Tian X; Kalymbetov A; Weissmann N; Grimminger F; Kretschmer A; Stasch JP; Seeger W; Ghofrani HA; Schermuly RT
PLoS One; 2012; 7(8):e43433. PubMed ID: 22912874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
